News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
266,568 Results
Type
Article (14194)
Company Profile (282)
Press Release (252092)
Section
Business (79549)
Career Advice (153)
Deals (13229)
Drug Delivery (35)
Drug Development (50445)
Employer Resources (31)
FDA (5713)
Job Trends (5129)
News (144433)
Policy (10028)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (1)
2024 BioMidwest Digital (4)
2024 Bio NC Digital (4)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (11)
2024 Biotech Beach Digital (5)
2024 Biotech Beach Standard (3)
2024 Genetown Digital (7)
2024 Genetown Standard (7)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (4)
2024 Pharm Country Standard (4)
2025 BioForest Digital (3)
2025 Lone Star Bio Digital (3)
2026 BioMidwest Elite (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Elite (1)
Academia (910)
Accelerated approval (2)
Adcomms (12)
Allergies (49)
Alliances (21640)
ALS (60)
Alzheimer's disease (824)
Antibody-drug conjugate (ADC) (86)
Approvals (5729)
Artificial intelligence (108)
Autoimmune disease (10)
Automation (5)
Bankruptcy (104)
Best Places to Work (4563)
BIOSECURE Act (5)
Biosimilars (40)
Biotechnology (232)
Bladder cancer (43)
Brain cancer (19)
Breast cancer (139)
Cancer (1284)
Cardiovascular disease (103)
Career advice (132)
Career pathing (2)
CAR-T (107)
Cell therapy (305)
Cervical cancer (7)
Clinical research (40868)
Collaboration (497)
Compensation (218)
Complete response letters (13)
COVID-19 (1034)
CRISPR (36)
C-suite (141)
Cystic fibrosis (76)
Data (1346)
Denatured (11)
Depression (28)
Diabetes (124)
Diagnostics (1294)
Digital health (3)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (77)
Drug pricing (28)
Drug shortages (3)
Duchenne muscular dystrophy (81)
Earnings (29645)
Editorial (17)
Employer branding (4)
Employer resources (29)
Events (48112)
Executive appointments (396)
FDA (6328)
Featured Employer (32)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (463)
Gene editing (87)
Generative AI (9)
Gene therapy (228)
GLP-1 (353)
Government (1074)
Grass and pollen (2)
Guidances (18)
Healthcare (6587)
Huntington's disease (21)
IgA nephropathy (20)
Immunology and inflammation (79)
Indications (18)
Infectious disease (1096)
Inflammatory bowel disease (110)
Inflation Reduction Act (8)
Influenza (18)
Intellectual property (55)
Interviews (17)
IPO (7263)
IRA (11)
Job creations (860)
Job search strategy (127)
Kidney cancer (6)
Labor market (4)
Layoffs (200)
Leadership (2)
Legal (1386)
Liver cancer (30)
Lung cancer (184)
Lymphoma (81)
Machine learning (1)
Management (7)
Manufacturing (115)
MASH (48)
Medical device (2590)
Medtech (2591)
Mergers & acquisitions (6252)
Metabolic disorders (362)
Multiple sclerosis (51)
NASH (13)
Neurodegenerative disease (57)
Neuropsychiatric disorders (23)
Neuroscience (1188)
NextGen: Class of 2025 (2019)
Non-profit (852)
Northern California (1532)
Now hiring (21)
Obesity (184)
Opinion (100)
Ovarian cancer (59)
Pain (40)
Pancreatic cancer (51)
Parkinson's disease (104)
Partnered (8)
Patents (109)
Patient recruitment (66)
Peanut (35)
People (25511)
Pharmaceutical (48)
Pharmacy benefit managers (5)
Phase I (14427)
Phase II (19014)
Phase III (12022)
Pipeline (687)
Podcasts (46)
Policy (35)
Postmarket research (852)
Preclinical (6059)
Press Release (30)
Prostate cancer (53)
Psychedelics (35)
Radiopharmaceuticals (212)
Rare diseases (272)
Real estate (1415)
Recruiting (12)
Regulatory (8552)
Reports (15)
Research institute (936)
Resumes & cover letters (17)
Rett syndrome (3)
RNA editing (3)
RSV (10)
Schizophrenia (55)
Series A (91)
Series B (59)
Service/supplier (1)
Sickle cell disease (37)
Southern California (1359)
Special edition (11)
Spinal muscular atrophy (117)
Sponsored (11)
Startups (1980)
State (1)
Stomach cancer (4)
Supply chain (18)
The Weekly (33)
United States (11997)
Vaccines (204)
Venture capitalists (28)
Webinars (7)
Weight loss (105)
Women's health (15)
Worklife (2)
Date
Today (40)
Last 7 days (377)
Last 30 days (1484)
Last 365 days (19976)
2025 (4599)
2024 (20554)
2023 (22416)
2022 (26825)
2021 (27808)
2020 (23359)
2019 (16232)
2018 (11746)
2017 (13754)
2016 (11848)
2015 (14360)
2014 (10397)
2013 (7489)
2012 (7544)
2011 (7624)
2010 (7440)
Location
Africa (148)
Alabama (38)
Alaska (2)
Arizona (52)
Arkansas (5)
Asia (17214)
Australia (2915)
California (3486)
Canada (1045)
China (321)
Colorado (135)
Connecticut (143)
Delaware (87)
Europe (37026)
Florida (408)
Georgia (106)
Idaho (16)
Illinois (209)
India (8)
Indiana (85)
Iowa (1)
Japan (69)
Kansas (59)
Kentucky (5)
Louisiana (3)
Maine (11)
Maryland (442)
Massachusetts (2745)
Michigan (69)
Minnesota (134)
Mississippi (1)
Missouri (22)
Montana (14)
Nebraska (4)
Nevada (15)
New Hampshire (14)
New Jersey (873)
New Mexico (12)
New York (949)
North Carolina (516)
North Dakota (4)
Northern California (1532)
Ohio (107)
Oklahoma (9)
Oregon (21)
Pennsylvania (669)
Puerto Rico (3)
Rhode Island (15)
South America (208)
South Carolina (4)
Southern California (1359)
Tennessee (25)
Texas (399)
Utah (48)
Virginia (67)
Washington D.C. (28)
Washington State (317)
Wisconsin (13)
266,568 Results for "clarus therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
BioMidwest
Clarus Therapeutics Holdings, Inc. Announces Completion of Auction for Sale of JATENZO® and Selection of Tolmar, Inc. as Successful Bidder
Clarus Therapeutics Holdings, Inc. (Clarus) (OTC: CRXTQ) announced today that, subject to entry into definitive documentation, it and its wholly-owned subsidiary, Clarus Therapeutics, Inc., selected Tolmar, Inc., (Buffalo Grove, IL) as the winning bidder in a competitive bidding and auction proceeding for the sale of JATENZO (and certain related assets).
October 18, 2022
·
4 min read
BioMidwest
Clarus Therapeutics Announces Issuance of Patent Covering JATENZO® (testosterone undecanoate)
Clarus Therapeutics Holdings, Inc. (“Clarus”) (Nasdaq:CRXT), today announced that the United States Patent and Trademark Office (USPTO) has issued a new patent for claims that cover Clarus’ oral testosterone replacement product, JATENZO (testosterone undecanoate).
May 18, 2022
·
8 min read
Business
Clarus Therapeutics Reports Second Quarter 2022 Financial and Operating Results and Announces Workforce Reduction
Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies, today reported financial results for the second quarter of 2022.
August 18, 2022
·
11 min read
BioMidwest
Clarus Therapeutics Announces Notice of Allowance for Additional Patent Claims Covering JATENZO® (testosterone undecanoate)
Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), today announced that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for additional claims that cover its oral testosterone replacement product, JATENZO (testosterone undecanoate).
July 28, 2022
·
8 min read
Business
Clarus Therapeutics to Report First Quarter 2022 Financial and Operating Results
Clarus Therapeutics Holdings, Inc. (“Clarus”) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced it will release its first quarter 2022 financial and operating results on Monday, May 16, 2022, after the market closes.
May 12, 2022
·
1 min read
BioMidwest
Clarus Therapeutics Announces $15 Million Private Placement
Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), today announced that it has entered into a definitive agreement to sell securities in a private placement with a leading healthcare investor.
December 3, 2021
·
4 min read
Deals
Clarus Therapeutics Holdings, Inc. Announces Plan for Near-Term Sale of JATENZO® Using Structured Process Through Chapter 11 of the U.S. Bankruptcy Code
Clarus Therapeutics Holdings, Inc. announced that it, together with its wholly-owned subsidiary Clarus Therapeutics, Inc., has filed voluntary petitions under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware.
September 5, 2022
·
6 min read
BioMidwest
Clarus Therapeutics to Present at the Oppenheimer 32nd Annual Healthcare Conference
Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced that it will present virtually at the Oppenheimer 32nd Annual Healthcare Conference.
March 10, 2022
·
1 min read
Business
Clarus Therapeutics to Report Fourth Quarter and Full Year 2021 Financial and Operating Results
Clarus Therapeutics Holdings, Inc. (“Clarus”) (Nasdaq:CRXT), today announced it will release its fourth quarter and full year 2021 financial and operating results on Wednesday, March 30, 2022, after the market closes.
March 29, 2022
·
1 min read
Business
Clarus Therapeutics Reports First Quarter 2022 Financial and Operating Results
Clarus Therapeutics Holdings, Inc., a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, reported financial results for the first quarter of 2022.
May 16, 2022
·
9 min read
1 of 26,657
Next